

sRMP

Part VI: Summary of the risk management plan

Summary of risk management plan for Kalciumklorid Abboxia (calcium chloride)

This is a summary of the risk management plan (RMP) for Kalciumklorid Abboxia. The RMP details important risks of Kalciumklorid Abboxia, how these risks can be minimised, and how more information will be obtained about Kalciumklorid Abboxia's risks and uncertainties (missing information).

Kalciumklorid Abboxia's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Kalciumklorid Abboxia should be used.

I. The medicine and what it is used for

Kalciumklorid Abboxia is authorised for use in hypocalcaemia, calcium channel blocker overdose, hypermagnesiumemia or hyperkalaemia in adults and children. It contains calcium chloride dihydrate as the active substance and it is given by intravenous injection.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Kalciumklorid Abboxia, together with measures to minimise such risks and the proposed studies for learning more about Kalciumklorid Abboxia's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Kalciumklorid Abboxia are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Kalciumklorid Abboxia. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

There are no important risks for Kalciumklorid Abboxia.

II.C Post-authorisation development plan**II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Kalciumklorid Abboxia.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Kalciumklorid Abboxia.